+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Complex Regional Pain Syndrome - Pipeline Review, H2 2020

  • ID: 5146836
  • Drug Pipelines
  • August 2020
  • Region: Global
  • 65 pages
  • Global Markets Direct

FEATURED COMPANIES

  • Allergan Ltd
  • Bexson Biomedical Inc
  • NeuroTherpia Inc
  • Piramal Enterprises Ltd
  • Tetra Bio-Pharma Inc
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Complex Regional Pain Syndrome - Pipeline Review, H2 2020, provides an overview of the Complex Regional Pain Syndrome (Central Nervous System) pipeline landscape.

Complex regional pain syndrome (CRPS) is a chronic pain condition that most often affects one limb usually after an injury. CRPS is divided into two types: CRPS-I (Individuals without a confirmed nerve injury) and CRPS-II (when there is an associated, confirmed nerve injury). Symptoms include stiffness in affected joints, changes in nail and hair growth patterns, dystonia and abnormal sweating pattern. Treatment includes bisphosphonates, non-steroidal anti-inflammatory drugs, opioids and local anesthetic creams.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Complex Regional Pain Syndrome - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Complex Regional Pain Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Complex Regional Pain Syndrome (Central Nervous System) pipeline guide also reviews the key players involved in therapeutic development for Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Phase 0 and Preclinical stages are 1, 3, 1 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Complex Regional Pain Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Complex Regional Pain Syndrome (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Complex Regional Pain Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Complex Regional Pain Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Complex Regional Pain Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Complex Regional Pain Syndrome (Central Nervous System)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize the emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Complex Regional Pain Syndrome (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Complex Regional Pain Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Allergan Ltd
  • Bexson Biomedical Inc
  • NeuroTherpia Inc
  • Piramal Enterprises Ltd
  • Tetra Bio-Pharma Inc
Introduction

Report Coverage
  • Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Overview
  • Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Therapeutics Development
Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Companies Involved in Therapeutics Development
  • Allergan Ltd
  • Bexson Biomedical Inc
  • Bio-Pharm Solutions Co Ltd
  • Biohaven Pharmaceutical Holding Company Ltd
  • NeuroTherpia Inc
  • Piramal Enterprises Ltd
  • Takeda Pharmaceutical Co Ltd
  • Tetra Bio-Pharma Inc
Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Drug Profiles

Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Dormant Projects
  • Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Product Development Milestones
Featured News & Press Releases

Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact
  • Disclaimer
List of Tables
  • Number of Products under Development for Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Pipeline by Allergan Ltd, H2 2020
  • Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Pipeline by Bexson Biomedical Inc, H2 2020
  • Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Pipeline by Bio-Pharm Solutions Co Ltd, H2 2020
  • Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H2 2020
  • Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Pipeline by NeuroTherpia Inc, H2 2020
  • Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Pipeline by Piramal Enterprises Ltd, H2 2020
  • Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2020
  • Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Pipeline by Tetra Bio-Pharma Inc, H2 2020
  • Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Dormant Projects, H2 2020
List of Figures
  • Number of Products under Development for Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products by Targets, H2 2020
  • Number of Products by Stage and Targets, H2 2020
  • Number of Products by Mechanism of Actions, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Top 10 Routes of Administration, H2 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2020
  • Number of Products by Molecule Types, H2 2020
  • Number of Products by Stage and Molecule Types, H2 2020
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Allergan Ltd
  • Bexson Biomedical Inc
  • Bio-Pharm Solutions Co Ltd
  • Biohaven Pharmaceutical Holding Company Ltd
  • NeuroTherpia Inc
  • Piramal Enterprises Ltd
  • Takeda Pharmaceutical Co Ltd
  • Tetra Bio-Pharma Inc
Note: Product cover images may vary from those shown
Adroll
adroll